含有RAS/RAF蛋白干扰单元的多目标HDAC抑制剂
Yuanjiang Wang1,2, Jianluo Zhang1, Kun Li1
1Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, PR China.
Journal of medicinal chemistry
|January 23, 2024
概括
新的抗癌药物,XSJ-7和XSJ-10,向激素脱乙酶 (HDAC) 和RAS通路. 在临床前模型中,XSJ-10表现出强大的抗瘤活性和有利的药理动力学.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 基斯脱乙酶 (HDAC) 抑制剂在癌症治疗中至关重要.
- 利格索塞蒂布向RAS信号通路,这是许多癌症的关键驱动因素.
- 开发多目标药物为提高疗效提供了一个有前途的战略.
研究的目的:
- 设计和合成新的多目标HDAC抑制剂.
- 研究这些化合物的抗增殖和抗瘤活性.
- 阐明抗癌机制,重点关注RAS途径和HDAC抑制.
主要方法:
- 合成具有结合组的rigosertib类似物.
- 针对各种癌症细胞系的体外抗增殖试验.
- 对不同HDAC亚型的抑制测定.
- 在HT-29异种移植小鼠模型中的体内疗效研究.
- 药物动力学分析和毒性评估.
- 西部斑点分析以评估信号通路调制.
主要成果:
- 两个化合物,XSJ-7和XSJ-10,表现出显著的抗增殖作用.
- 与SAHA相比,XSJ-10表现出优越的HDAC抑制.
- 在体内,XSJ-10显示出增强的抗瘤活性和中度的药理动力学.
- XSJ-10有效诱导癌细胞亡并抑制瘤生长.
- 证实了RAS-RAF-MEK-ERK通路的抑制和HDAC3乙化.
结论:
- 开发了新的基于rigosertib的HDAC抑制剂 (XSJ-7,XSJ-10).
- 通过双重抑制HDAC和RAS通路,XSJ-10显示出强大的抗癌活性.
- XSJ-10代表了进一步临床前和临床开发的有希望的候选人.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Small GTPases - Ras and Rho
4.0K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
4.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


